Studies of Receptor Tyrosine Kinase Transmembrane Domain Interactions: The EmEx-FRET Method
- 247 Downloads
The energetics of transmembrane (TM) helix dimerization in membranes and the thermodynamic principles behind receptor tyrosine kinase (RTK) TM domain interactions during signal transduction can be studied using Förster resonance energy transfer (FRET). For instance, FRET studies have yielded the stabilities of wild-type fibroblast growth factor receptor 3 (FGFR3) TM domains and two FGFR3 pathogenic mutants, Ala391Glu and Gly380Arg, in the native bilayer environment. To further our understanding of the molecular mechanisms of deregulated FGFR3 signaling underlying different pathologies, we determined the effect of the Gly382Asp FGFR3 mutation, identified in a multiple myeloma cell line, on the energetics of FGFR3 TM domain dimerization. We measured dimerization energetics using a novel FRET acquisition and processing method, termed “emission-excitation FRET (EmEx-FRET),” which improves the precision of thermodynamic measurements of TM helix association. The EmEx-FRET method, verified here by analyzing previously published data for wild-type FGFR3 TM domain, should have broad utility in studies of protein interactions, particularly in cases when the concentrations of fluorophore-tagged molecules cannot be controlled.
KeywordsReceptor tyrosine kinase Transmembrane domain FRET
We thank our colleagues Edwin Li and William C. Wimley for valuable discussions. This work was supported by NIH grant GM068619, NSF grant MCB 0315663 and Research Scholar grant RSG-04-201-01 from the American Cancer Society (to K. H.).
- Lakowicz JR (1999) Principles of Fluorescence Spectroscopy. Kluwer Academic/Plenum Publishers, New YorkGoogle Scholar
- Otsuki T, Nakazawa N, Taniwaki M, Yamada O, Sakaguchi H, Wada H, Yawata Y, Ueki A (1998) Establishment of a new human myeloma cell line, KMS-18, having t(4;14)(p16.3;q32.3) derived from a case phenotypically transformed from Ig A-lambda to BJP-lambda, and associated with hyperammonemia. Int J Oncol 12:545–552PubMedGoogle Scholar
- van Rhijin B, van Tilborg A, Lurkin I, Bonaventure J, de Vries A, Thiery JP, van der Kwast TH, Zwarthoff E, Radvanyi F (2002) Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 10:819–824CrossRefGoogle Scholar